Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation ; volume:14 ; number:1 ; day:21 ; month:10 ; year:2024 ; pages:1-8 ; date:12.2024
Scientific reports ; 14, Heft 1 (21.10.2024), 1-8, 12.2024
- Creator
-
Einarsdottir, Sigrun
Al-Dury, Samer
Fridriksson, Ellen
Andius, Linn Dahlsten
Wang, Hao
Sharba, Sinan
Mountagui, Amin
Waern, Johan
Ringlander, Johan
Martner, Anna
Hellstrand, Kristoffer
Waldenström, Jesper
Lagging, Martin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-74712-x
- URN
-
urn:nbn:de:101:1-2501092127331.464163289898
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Einarsdottir, Sigrun
- Al-Dury, Samer
- Fridriksson, Ellen
- Andius, Linn Dahlsten
- Wang, Hao
- Sharba, Sinan
- Mountagui, Amin
- Waern, Johan
- Ringlander, Johan
- Martner, Anna
- Hellstrand, Kristoffer
- Waldenström, Jesper
- Lagging, Martin
- SpringerLink (Online service)
Other Objects (12)
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19